Related Experiment Video
Updated: Aug 16, 2026

Modeling Dysplastic and Functional Lung Alveolar Repair after Influenza Infection
Published on: September 19, 2025
Cost-benefit of stockpiling drugs for influenza pandemic
Ran D Balicer1, Michael Huerta, Nadav Davidovitch
1Ministry of Health, Jerusalem, Israel. rbalicer@netvision.net.il
Abstract:
We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.
More Related Videos
08:52Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Published on: July 26, 2019
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Dosage Regimens: Partial Pharmacokinetic Parameters
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Pharmacokinetics: Drug–Food and Drug–Viral Interactions